FITC Annexin V

Pricing & Availability
Regulatory Status
RUO
Other Names
Annexin A5
Ave. Rating
Submit a Review
Product Citations
publications
AnnexinV_FITC_092908.jpg
Human T leukemia cell line, Jurkat, non-treated (top) or treated (bottom) with BioLegend’s anti-human CD95 (EOS9.1) mAb (cat. 305704) for 6 hours, then stained with Annexin V-FITC and Propidium Iodide (PI) (cat. 421301)
  • AnnexinV_FITC_092908.jpg
    Human T leukemia cell line, Jurkat, non-treated (top) or treated (bottom) with BioLegend’s anti-human CD95 (EOS9.1) mAb (cat. 305704) for 6 hours, then stained with Annexin V-FITC and Propidium Iodide (PI) (cat. 421301)
  • B_AnnexinV_FITC_092908.jpg
See FITC spectral data
Cat # Size Price Quantity Check Availability Save
640905 25 tests $77
Check Availability


Need larger quantities of this item?
Request Bulk Quote
640906 100 tests $182
Check Availability


Need larger quantities of this item?
Request Bulk Quote
640945 300 tests $380
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Annexin V (or Annexin A5) is a member of the annexin family of intracellular proteins that binds to phosphatidylserine (PS) in a calcium-dependent manner. PS is normally only found on the intracellular leaflet of the plasma membrane in healthy cells, but during early apoptosis, membrane asymmetry is lost and PS translocates to the external leaflet. Fluorochrome-labeled Annexin V can then be used to specifically target and identify apoptotic cells. Annexin V Binding Buffer (cat. no. 422201) is recommended for use with Annexin V staining.Annexin V binding alone cannot differentiate between apoptotic cells and necrotic. Therefore, we recommend using our Helix NP™ Blue (Cat. No. 425305), Helix NP™ Green (Cat.  No. 425303) or Helix NP™ NIR (Cat. No. 425301). Early apoptotic cells will exclude 7-AAD and PI, while late stage apoptotic cells and necrotic cells will stain positively, due to the passage of these dyes into the nucleus where they bind to DNA.

Product Details
Technical data sheet

Product Details

Verified Reactivity
All mammalian species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The purified protein was conjugated with FITC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The Annexin V solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per 100,000 - million cells in a 100 µl volume of Annexin V Binding Buffer (Cat No. 422201). It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Annexin V Staining
1. Wash cells twice with cold BioLegend cell staining buffer (Cat. No. 420201) and then resuspend cells in Annexin V Binding Buffer (Cat. No. 422201) at a concentration of 1x106 cells/mL.
2. Transfer 100 µL of cell suspension in 5 ml test tube.
3. Add 5 µL of FITC Annexin V.
4. Add 10 µL of PI solution (Cat. No. 421301) or 7-AAD (Cat. No. 420403/420404).
5. Gently vortex the cells and incubate for 15 min at RT (25°C) in the dark.
6. Add 400 µL of Annexin V Binding Buffer (Cat. No. 422201) to each tube. Analyze by flow cytometry.


For a better experience detecting apoptosis, we now recommend Apotracker™. Cell staining with Apotracker™ is Calcium independent. Thus, no special buffers are required, and the protocol can be shortened for single-step co-staining with other reagents.

Application References

(PubMed link indicates BioLegend citation)
  1. Koopman G, et al. 1994. Blood 84:1415.
  2. Vermes I, et al. 1995. J. Immunol. Methods 184:39.
  3. Dachary-Prigent J, et al. 1993. Blood 81:2554.
  4. Sekine C, et al. 2009. Int Immunol. PubMed
  5. Grujic M, et al. 2010. J. Immunol. 185:1730. PubMed
  6. Mulik RS, et al. 2010. Int J Pharm. 398:190. PubMed
  7. Gupta A, et al. 2011. Leuk Res. 35:1498. PubMed
  8. Speth C,et al. 2013. J Infect Dis. 207:823. PubMed
  9. Wang Q, et al. 2013. Genes Dev. 27:615. PubMed
  10. Gill K, et al. 2013. Biocheim Biophys Acta. 830:2763. PubMed
  11. Juel HB, et al. 2013. PLoS One. 8:64619. PubMed
  12. Hellmann J, et al. 2013. J. Immunol. 191:1383. PubMed
  13. Sequier S, et al. 2013. PLoS One. 8:70937. PubMed
  14. Galski H, et al. 2013. Biochem Pharmacol. 86:584. PubMed
  15. Chen YL, et al. 2013. J Exp Med. PubMed
  16. Lin WH, et al. 2014. PLoS One. 9:83160. PubMed
  17. Salge-Bartles U, 2014. Thromb res. 133:244. PubMed
  18. Zhang X, et al. 2014. Acta Biochim Biophys Sin. 46:261. PubMed
  19. Intermann J, et al. 2014. Cell Signal. 26:1567. PubMed
  20. de Vires M, 2014. Am J Physiol Lung Cell Mol Physiol. 307:240. PubMed
  21. M Parrula MC, et al. 2014. Virus Res. 189:206. PubMed
  22. Passaro C, et al. 2014. Mol Oncol. 9:78. PubMed
  23. Tsou WI, et al. 2014. J Biol Chem. 289:25750. PubMed
  24. Awojoodu AO, et al. 2014. Blood. 124:1941. PubMed
  25. Xiong R, et al. 2014. Toxicol Appl Pharmacol. 280:285. PubMed
  26. Liu J, et al. 2015. J Mol Cell Cardiol. 80:10. PubMed
Product Citations
  1. Speth C, et al. 2013. J Infect Dis. 207:823. PubMed
  2. Wang Q, et al. 2013. Genes Dev. 27:615. PubMed
  3. Gill K, et al. 2013. Biochim Biophys Acta. 1830:2763. PubMed
  4. Juel H, et al. 2013. PLoS One. 8:64619. PubMed
  5. Gupta A, et al. 2011. Leuk Res. 35:1498. PubMed
  6. Mulik R, et al. 2010. Int J Pharm. 398:190. PubMed
  7. Hellmann J, et al. 2013. J Immunol. 191:1383. PubMed
  8. Séguier S, et al. 2013. PLoS One. 8:70937. PubMed
  9. Passaro C, et al. 2013. Endocr Relat Cancer. 20:633. PubMed
  10. Galski H, et al. 2013. Biochem Pharmacol. 86:584. PubMed
  11. Chen Y, et al. 2013. J Exp Med. 210:2515. PubMed
  12. Lin W, et al. 2014. PLoS One. 9:83160. PubMed
  13. Salge-Bartels U, et al. 2014. Thromb Res. 133:244. PubMed
  14. Zhang X, et al. 2014. Acta Biochim Biophys Sin. 46:261. PubMed
  15. Intemann J, et al. 2014. Cell Signal. 26:1567. PubMed
  16. Vries M, et al. 2014. Am J Physiol Lung Cell Mol Physiol. 307:240. PubMed
  17. Parrula M, et al. 2014. Virus Res. 189:206. PubMed
  18. Passaro C, et al. 2014. Mol Oncol. 9:78. PubMed
  19. Tsou W, et al. 2014. J Biol Chem. 289:25750. PubMed
  20. Awojoodu A, et al. 2014. Blood. 124:1941. PubMed
  21. Xiong R, et al. 2014. Toxicol Appl Pharmacol. 280:285. PubMed
  22. Liu J, et al. 2015. J Mol Cell Cardiol. 80:10. PubMed
  23. Lhuillier C, et al. 2015. J Biol Chem. 290: 16797 - 16811. PubMed
  24. CO L, et al. 2015. Nat Commun. 6: 7739. PubMed
  25. Brigger D, et al. 2015. Cell Death Dis. 6: e1861. PubMed
  26. Fujii T, et al. 2015. Proc Natl Acad Sci U S A. 112: 12800 - 12805. PubMed
  27. Xiong R, et al. 2015. Mol Pharmacol. 88: 1045 - 1054. PubMed
  28. Polak R, et al. 2015. Blood. 126: 2404 - 2414. PubMed
  29. Slone E, et al. 2015. J Leukoc Biol. 98: 791 - 804. PubMed
  30. Kumai T, et al. 2015. Sci Rep. 5:16280. PubMed
  31. Carlsson J, et al. 2015. PLoS One. 10: 0143741. PubMed
  32. Cardoso B, et al. 2015. PLoS One. 10: 0143897. PubMed
  33. Ligtenberg M, et al. 2016. J Immunol. 196: 759 - 766. PubMed
  34. Akane K, et al. 2016. Proc Natl Acad Sci U S A. 113: 2460 - 2465. PubMed
  35. Derudder E, et al. 2016. Proc Natl Acad Sci U S A. 113: 5065-5070. PubMed
  36. Gedye C, et al. 2016. Sci Rep. 6: 25220. PubMed
  37. O'Neill K, et al. 2016. Genes Dev. 30: 973-988. PubMed
  38. Kitayama J, et al. 2016. PLoS One. 11: 0154542. PubMed
  39. Zhang J, et al. 2016. Cell Death Dis. 7:e2266. PubMed
  40. Soprano M, et al. 2016. PLoS One. 11: 0155970. PubMed
  41. Wang D, et al. 2016. J Cell Sci. 129: 2261 - 2272. PubMed
  42. Langsch S, et al. 2016. Cancer Res . 76: 4160 - 4169. PubMed
  43. Jones P, et al. 2016. J Biol Chem. 291: 16318 - 16327. PubMed
  44. Pfalzgraff A, et al. 2016. Sci Rep. 6:31577. PubMed
  45. Uchtenhagen H, et al. 2016. Nat Commun. 7:12614. PubMed
  46. Chheda Z, et al. 2016. J Immunol. 197: 2016 - 2026. PubMed
  47. Becker A, et al. 2016. Sci Rep. 6: 33847. PubMed
  48. Hrdinka M, et al. 2016. PLoS One. 11: 0162863. PubMed
  49. Geiger R, et al. 2016. Cell. 167:829-842. PubMed
  50. Liu B, et al. 2016. J Biol Chem. 291: 23869 - 23881. PubMed
  51. Yoon Y, et al. 2016. Stem Cell Reports. 7:840-853. PubMed
  52. L Chang, Y Li, D Kaplan 2016. Sci Rep. 6:36862. PubMed
  53. Douguet L, et al. 2016. PLoS One. 11:e0166164. PubMed
  54. Toutounchian J, et al. 2016. Mol Pharmacol. 91(1):1-13. PubMed
  55. Coutaz M, et al. 2016. Sci Rep. 6:39117. PubMed
  56. Herold N, et al. 2017. Nat Med. 23:256-263. PubMed
  57. Faria M, et al. 2017. PLoS One. 12(2):e0172689. PubMed
  58. Clements KE, et al. 2020. Nat Commun. 4.706944444. PubMed
  59. Schleicher EM, et al. 2020. PLoS Genet. 16:e1009176. PubMed
  60. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  61. Huang YL, et al. 2020. Elife. 9:00. PubMed
  62. Dewdney B, et al. 2020. Sci Rep. 10:16769. PubMed
  63. Alcon C, et al. 2020. Cell Death Dis. 0.898611111. PubMed
  64. Cai Z, et al. 2020. Cell Rep. 31:107816. PubMed
  65. Kang JH, et al. 2020. Cell Death Dis. 0.803472222. PubMed
  66. Dhoonmoon A, et al. 2020. Nucleic Acids Res. 48:7252. PubMed
  67. Ramalingam P, et al. 2020. J Exp Med. 217:00:00. PubMed
  68. Kim EH, et al. 2020. Elife. 9:00. PubMed
  69. Pajarillo E, et al. 2020. J Biol Chem. 295:3040. PubMed
  70. Pahari S, et al. 2020. Autophagy. 1.375694444. PubMed
  71. Zhang Y, et al. 2021. Cell Death Dis. 0.563194444. PubMed
  72. Xie S, et al. 2021. Sci Rep. 0.660416667. PubMed
  73. Siddhartha V, et al. 2017. Artif Cells Nanomed Biotechnol . 10.1080/21691401.2017.1313267. PubMed
  74. Beeravolu N, McKee C, Chaudhry G 2017. J App Toxicol. 10.1002/jat.3469. PubMed
  75. Zheng Q, et al. 2017. Mol Oncol. 10.1002/1878-0261.12056. PubMed
  76. Karavasili C, et al. 2017. International Journal of Pharmaceutics. 10.1016/j.ijpharm.2017.05.061. PubMed
  77. Wang M, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.097. PubMed
  78. Chiani M, et al. 2017. Artif Cells Nanomed Biotechnol. 10.1080/21691401.2017.1337029. PubMed
  79. Hafez A, et al. 2017. Oncogenesis. 10.1038/oncsis.2017.46. PubMed
  80. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  81. Liu Y, et al. 2017. Acta Biomater. 10.1016/j.actbio.2017.08.021. PubMed
  82. Kamiyama N, et al. 2017. Antiviral Res. 10.1016/j.antiviral.2017.08.007. PubMed
  83. Thomas A, et al. 2017. PLoS One.. 10.1371/journal.pone.0183542. PubMed
  84. Espinosa-Cueto P, et al. 2017. PLoS One.. 10.1371/journal.pone.0182126. PubMed
  85. Zervou S, et al. 2017. PLoS One.. 10.1371/journal.pone.0182994. PubMed
  86. Naqvi N,et al. 2017. Sci Rep.. 10.1038/s41598-017-12753-1. PubMed
  87. Kuntz E, et al. 2017. Nat Med. 10.1038/nm.4399. PubMed
  88. Ki H, et al. 2017. Biomed Pharmacother. 10.1016/j.biopha.2017.09.118. PubMed
  89. Schuler F, et al. 2017. Nat Commun. . 10.1038/s41467-017-01850-4. PubMed
  90. Thanuthanakhun N, et al. 2017. PLoS One. . 10.1371/journal.pone.0187610. PubMed
  91. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  92. Yamauchi T et al. 2018. Cancer cell. 33(3):386-400 . PubMed
  93. Greenblatt SM, et al. 2018. Cancer Cell. 33:1111. PubMed
  94. Thompson PJ et al. 2019. Cell metabolism. 29(5):1045-1060 . PubMed
  95. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  96. Ni F, et al. 2019. Cell Stem Cell. 24:608. PubMed
  97. Litzenburger UM, et al. 2017. Genome Biol. 18:15. PubMed
  98. Noguchi F, et al. 2017. Mol Cancer Ther. 1.316666667. PubMed
  99. Rauzan M, et al. 2017. PLoS One. 12:e0174107. PubMed
  100. He J, et al. 2017. FASEB J. 31:2893. PubMed
  101. Rajavel T, et al. 2017. Sci Rep. 2.665277778. PubMed
  102. Pirali T, et al. 2017. ChemMedChem. 1.570833333. PubMed
  103. Feng W, et al. 2017. Nat Commun. 0.697916667. PubMed
  104. Venter C, et al. 2017. Cell Physiol Biochem. 43:1288. PubMed
  105. Montero–Herradón S, et al. 2017. Organogenesis. 0.675. PubMed
  106. Lee HW, et al. 2018. Am J Physiol Renal Physiol. 314:F280. PubMed
  107. Lopes–Coelho F, et al. 2017. Oncotarget. 8:82803. PubMed
  108. Lim JA, et al. 2018. BMC Cancer. 0.860416667. PubMed
  109. Bouhaddou M, et al. 2018. PLoS Comput Biol. 14:e1005985. PubMed
  110. Jones PD, et al. 2018. Arterioscler Thromb Vasc Biol. 38:1711. PubMed
  111. Nunes SC, et al. 2018. Sci Rep. 6.939583333. PubMed
  112. Schleicher EM, et al. 2018. Nucleic Acids Res. 46:8908. PubMed
  113. Clements KE, et al. 2018. Nucleic Acids Res. 46:8898. PubMed
  114. Zhao CC, et al. 2018. Oncol Rep. 40:3392. PubMed
  115. Yao Z, et al. 2018. J Virol. 92:00:00. PubMed
  116. Kumar S, et al. 2018. Cancers (Basel). 0.724305556. PubMed
  117. Sharif T, et al. 2018. Autophagy. 1.101388889. PubMed
  118. Eichelmann AK, et al. 2018. Sci Rep. 8:17553. PubMed
  119. Santos LC, et al. 2019. Nat Commun. 1.328472222. PubMed
  120. Sales–Dias J, et al. 2019. PLoS One. 14:e0217002. PubMed
  121. Zheng M, et al. 2019. Proc Natl Acad Sci U S A. 116:12422. PubMed
  122. Kumar S, et al. 2019. Int J Cancer. 146:1652. PubMed
  123. Vancsik T, et al. 2019. Cancer Med. 3.313888889. PubMed
  124. Lyu X, et al. 2019. BMC Genomics. 1.235416667. PubMed
  125. Esteghamat F, et al. 2019. Nat Genet. 51:1233. PubMed
  126. Fang P, et al. 2019. Commun Biol. 0.315972222. PubMed
  127. Mendès C, et al. 2019. Sci Rep. 9:14107. PubMed
  128. Santos I, et al. 2019. Nutrients. 2.210416667. PubMed
  129. Blümel E, et al. 2019. Oncoimmunology. 8:e1641387. PubMed
  130. Young MM, et al. 2019. Cell Death Dis. 1.004861111. PubMed
  131. Di Somma S, et al. 2019. Cancers (Basel). 1.70625. PubMed
  132. Matsumoto A, et al. 2019. J Extracell Vesicles. 9:1696517. PubMed
  133. Jing Y, et al. 2019. J Allergy Clin Immunol. 144:1377. PubMed
  134. Gladow N, et al. 2020. PLoS One. 15:e0227734. PubMed
  135. Quan M, et al. 2019. Oncol Rep. 41:3051. PubMed
  136. Fortin J, et al. 2020. Cancer Cell. 37:308. PubMed
  137. Chen MS, et al. 2019. Mol Cancer Res. 17:697. PubMed
  138. Blümel E, et al. 2020. Oncoimmunology. 9:1751561. PubMed
  139. Labi V, et al. 2019. Genes Dev. 33:1673. PubMed
  140. Bowen ME, et al. 2019. Dev Cell. 50:212. PubMed
  141. Uriostegui–Arcos M, et al. 2020. Open Biol. 10:200050. PubMed
  142. Liu H, et al. 2020. Cell Death Dis. 0.767361111. PubMed
  143. Sekine C, et al. 2009. Int Immunol. 1.079861111. PubMed
  144. Grujic M, et al. 2010. J Immunol. 185:1730. PubMed
  145. Putheti P, et al. 2010. PLoS One. 5:e8706. PubMed
RRID
AB_2561291 (BioLegend Cat. No. 640905)
AB_2561292 (BioLegend Cat. No. 640906)
AB_2629519 (BioLegend Cat. No. 640945)

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
308 View all products for this Gene ID
UniProt
View information about Annexin V on UniProt.org

Related FAQs

How is your Annexin made and what sequence does it cover?

It is made in E. coli, covering human aa Met1-Asp320.

How does pH and staining temperature affect Annexin V-Phosphatidylserine binding?

Annexin-Phosphatidylserine binding is lost below pH 5.2 and with prolonged incubation over a temperature of 42°C.

Why do I need to use Annexin V Binding Buffer?

Annexin V binding requires the presence of calcium in the solution.  So, we provide Annexin V Binding Buffer (cat # 422201), which is optimized for the best performance of Annexin V staining.

Can I use RPMI during Annexin V staining?

It is best to follow protocol as described on the product data sheet. Moreover, RPMI 1640 has a relatively high concentration of phosphate and low calcium ion concentration, which negatively impacts Annexin binding to its target phosphatidylserine (PS). Measurement of cell death by using Annexin V may also be significantly affected by time of incubation on ice, calcium concentration, and type of medium.

Can I freeze Annexin V conjugates?

It should not be frozen as it will lead to loss of biological activity due to dimerization.

Is Annexin V suitable for conjugation with the Maxpar® kit for CyTOF®?

Maxpar® Labeling kits require the protein to be partially reduced, so the metal chelate can be introduced through an SH group in the hinge region of the reduced antibody. Human Annexin V contains only one Cysteine which was reported to be chemically inactive. Thus, the Maxpar® labeling protocol would not work with Annexin V, unless a free –SH group can be introduced to Annexin V.  For more information regarding SH-mediated conjugation of Annexin V please consult published papers such as this one.

Go To Top Version: 5    Revision Date: 04/20/2020

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login/Register
Remember me
Forgot your password? Reset Password
Request an Account